Thyroid SAT510 I-131 Therapy with Dosimetry for Advanced Thyroid Carcinoma: Recombinant TSH vs Thyroid Hormone Withdrawal

Authors

Dana Awad, University of Nebraska Medical CenterFollow
Jarod Hamsa, University of Nebraska Medical Center
Abbey Fingeret, University of Nebraska Medical CenterFollow
Craig M. Johnson, University of Nebraska Medical CenterFollow
Frank Rutar, University of Nebraska Medical CenterFollow
Carrie Carso, University of Nebraska Medical CenterFollow
Anupam Kotwal, University of Nebraska Medical CenterFollow
Anery Patel, University of Nebraska Medical CenterFollow
Angela Thornburg, University of Nebraska Medical Center
Whitney Sears Goldner, University of Nebraska Medical CenterFollow

Document Type

Article

Date of this Version

6-7-2023

Citation

J Endocrine Soc, Volume 7, Issue Supplement_1, October–November 2023

Comments

Used by permission.

Abstract

Background: Dosimetry can be used to calculate an optimal and safe dose of Iodine-131 (I-131) for treatment of advanced differentiated thyroid cancer (DTC). Thyroid hormone withdrawal (THW) is the preferred method of TSH elevation for I-131 therapy with dosimetry. At our institution, Recombinant TSH (RhTSH) is used in patients in whom prolonged hypothyroidism is deemed clinically unsafe or cannot tolerate THW. We aim to evaluate if RhTSH and THW are equivalent methods of preparation for I-131 therapy using dosimetry (I-131D).